TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes in fat mass via ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in levels of cognition using the Montreal Cognitive Assessment-Philippines (MoCA-P)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in levels of cognition using the Mini-Mental State Examination (MMSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in levels of cognition using the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: amount of dental changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amount of skeletal changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Segment-level percent diameter stenosis (%DS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: improving comorbidities associated with obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypertension Treatment Compliance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-Care Management in Chronic Diseases
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Fatigue symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: High-acuity rehospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Opioid use/abstinence
Endpoint domain: Adverse events/effects
Primary endpoint: Long-COVID symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant acceptance of the diet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Assess tolerance via patient diaries
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in ESSPRI score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in DASPRI score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain: Wrong-Baker FACES pain rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anxiety: Children's Anxiety Meter-State (CAM-S)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Numeric ranking scale (NRS) pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completeness of survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy of survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean inspired tidal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean expired tidal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Oral Antibiotic Treatment Failure
Endpoint domain: Adverse events/effects
Primary endpoint: VO2 consumption as a function of amputation level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VO2 consumption as a function of gait asymmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumption of VO2 as a function of prosthetic equipment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumption of VO2 as a function of walking condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Symptomatic Response
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Bb-specific ASCs per 10^6 PBMCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients with Pericarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Th2 immune cell population
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Achieving Complete Renal Response (CRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Primary cognitive efficacy endpoint 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence, Nature, and Severity of Treatment Emergent Adverse events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Primary imaging biomarker endpoint 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Cannulation Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Device- and procedure-related serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: changes of rectal flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in 30-seconds chair stand test (30-CST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of circulating immune cells in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Adverse events Possibly or probably related to previous AAV5-hFIX administration
Endpoint domain: Adverse events/effects
Primary endpoint: Neutralizing FIX antibodies (FIX inhibitors)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ALT/AST levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Dose Limiting Toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Antitumor Activity Assessed by Overall Response Rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants with antibiotic-related side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Solicited Local Adverse Events (AEs) for 7 Days After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Solicited Systemic AEs for 7 Days After Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the concentration versus time curve (AUC) of metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Quality of life of postmenopausal women
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Vaginal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Participants Achieving a ≥ 75% Improvement in F-VASI75
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vancomycin trough level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum serum concentration (Cmax) of DWJ1589 and DWC202315
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve (AUC)last of DWJ1589 and DWC202315
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving HiSCR 50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WSO BEAT Neurocardiology Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with endoscopic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in proportion of adherent participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hPFS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade III-IV acute graft versus host disease
Endpoint domain: Adverse events/effects
Primary endpoint: Confidence in Auditory Hallucination Assessment and Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge, Attitudes, and Perceived Empathy Toward Auditory Hallucinations
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Daily step count average
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Free living energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical Respiratory Score (CRS) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Phosphatidylethanol (PEth) concentrations on alcohol administration day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Breath alcohol concentrations on alcohol administration day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Self-reported drinking during the 28 days naturalistic drinking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: skill level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: DLT Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with RBC-TI response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of GRFS (graft versus host disease GVHD, relapse free survival)
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of occurrence of composite endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kujala Score (Anterior Knee Pain Scale - AKPS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in AHI (times/hour)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Incidence of Successful cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of Participants Achieving a ≥ 75% Improvement in F-VASI75
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mindful Attention Awareness
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: incidence of traumatic eyelid injuries
Endpoint domain: Adverse events/effects
Primary endpoint: nausea rate
Endpoint domain: Adverse events/effects
Primary endpoint: Detection of pericardial diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Part 3 score of the MDS-UPDRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Viral suppression rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: General Job Stress Scale (GJSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Therapeutic Relationship Evaluation Scale-Nurse Form (TRES-NF)
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Proportion of patients with complete data
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of respondents selecting a response - Feasibility
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Best-corrected High Contrast Visual Acuity (HCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: non-invasive keratograph break up time (NIKBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ocular discomfort symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of participants with Treatment Emerging Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Area under plasma concentration time curve from zero to infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the plasma concentration curve from zero to the last quantifiable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum observed plasma drug concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with treatment related serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with treatment related adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Physiological fistula maturity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory tract inflammation activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety of trastuzumab deruxtecan
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Mean Knowledge About FASD From Baseline to 6 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Personal Efficacy Mean From Baseline to 6 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Teaching Efficacy Means From Baseline to 6 Weeks
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Time to perform the vesicourethral anastomosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in mean pulmonary arterial pressure over cardiac output slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Osteoporosis awareness level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Frequency of SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: PROMIS Fatigue MELAS Short Form scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Groton Maze Learning Test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: International Digit Symbol Substitution Test scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Serum urate level < 5 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of treatment-emergent adverse event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Significant stimulation-induced adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in mean cumulative energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent correct on an assessment of transfer of skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in incidence of laboratory-confirmed COVID-19 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area Under Concentration Curve (AUC) of Baricitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Patient health questionnaire-14 (PHQ-14)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Positive valence systems scale-21 (PVSS-21)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in MRI images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ecological momentary assessment (EMA)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Dynamic leap balance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loughborough soccer passing test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loughborough soccer shooting test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: S180 sprinting test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vertical jumping test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agility with ball
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum dose administered
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Main germs incidence rate
Endpoint domain: Adverse events/effects
Primary endpoint: Variation in Hemoglobin (Hb) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Variation in Hypoxia inducible factor-2 alpha (HIF-2α) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation in Transforming growth factor β1 (TGF-β1) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peri-implant soft tissue changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: liver fibrosis screening acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Self-Injurious Thoughts and Behaviors
Endpoint domain: Adverse events/effects
Primary endpoint: Lead migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social motivation
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Neural circuit function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shared decision making
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fiber cross-sectional area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Myonuclei
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Skeletal muscle proteome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Plasma Concentrations of Losmapimod
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food Effect of Losmapimod
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Personal Acceptance Scale (PAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Broad Acceptance Scale (BAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Attributed Stigma Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Seizure-freedom
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Prosthesis Evaluation Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in 2 minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Dermatology Life Quality Index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants with Treatment-Emergent Laboratory Tumor Lysis Syndrome (TLS)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Hyperkalemia
Endpoint domain: Adverse events/effects
Primary endpoint: Number of positive tumor lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in non-vellus Total Area Hair Count (TAHC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Eczema Area and Severity Index (EASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Molecular testing rate of NSCLC prior to first systematic anti-tumor therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adjuvant or first line targeted therapy treatment rate in AGA NSCLC
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Mean absolute relative deviation (MARD) of venous plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Consensus Error Grid (CEG) for venous plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Clinically Significant Change From Baseline in Pulmonary Function Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in Whole Lung 15th Percentile Density as Measured by Computed Tomography (CT) Lung Densitometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Decrease in adipose tissue levels of inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Malay-MCDASf score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Gender dysphoria
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in Total Sleep Time (TST)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Progression of prediabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HCV antibody testing rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal concentration level of Devil's Claw metabolites, Cmax (ng/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach Cmax (h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Determination of terminal half-life of Devil's Claw, t 1/2 (h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical complete response (CR) or near-complete response (nCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-Report of Advance Directive
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Advance Care Planning Engagement Survey Score Change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of infants with at least one Grade 3 or higher Adverse Event (AE)
Endpoint domain: Adverse events/effects